AROAF (Aroa Biosurgery) Other Current Liabilities: $4.94 Mil (As of Mar. 2026)


AROAF Aroa Biosurgery Ltd AROAF
39 GF Score
Price $0.52
GF Value $0.71
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery Other Current Liabilities?

Aroa Biosurgery AROAF +35.24% 39 Other Current Liabilities is $4.94 Mil as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Aroa Biosurgery's other current liabilities for the quarter that ended in Mar. 2026 was $4.94 Mil.

Aroa Biosurgery's quarterly other current liabilities declined from Mar. 2025 ($3.29 Mil) to Sep. 2025 ($2.82 Mil) but then increased from Sep. 2025 ($2.82 Mil) to Mar. 2026 ($4.94 Mil).

Aroa Biosurgery's annual other current liabilities increased from Mar. 2024 ($2.87 Mil) to Mar. 2025 ($3.29 Mil) and increased from Mar. 2025 ($3.29 Mil) to Mar. 2026 ($4.94 Mil).

Aroa Biosurgery Other Current Liabilities Related Terms

Aroa Biosurgery Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Other Current Liabilities Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial 2.05 2.34 2.87 3.29 4.94

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 2.26 3.29 2.82 4.94
AROAF
39GF Score
Aroa Biosurgery Ltd AROAF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $4.94 Mil mean?
Aroa Biosurgery (AROAF) has a Other Current Liabilities of $4.94 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aroa Biosurgery.
Is Aroa Biosurgery's Other Current Liabilities too high?
Aroa Biosurgery's current Other Current Liabilities is $4.94 Mil. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Other Current Liabilities compare to ABT and SYK?
Aroa Biosurgery's Other Current Liabilities of $4.94 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aroa Biosurgery. Aroa Biosurgery's current Other Current Liabilities is $4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current Other Current Liabilities is $4.94 Mil. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current Other Current Liabilities is $4.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (AROAF) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for AROAF:

  • Other Current Liabilities: $4.94 Mil
  • GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
  • GF Score™: 39/100 with 1 warning sign

No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges ARX:Australia
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score

Get the complete analysis for AROAF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price
$0.71
GF Value